Risk for future stroke, MI, other cardiovascular events significantly reduced with intensive treatment targeting BP <120 mm Hg.
About one-half of persons with likely long COVID (LC) after first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection experience meaningful ...
GLP-1 receptor agonists carry a modestly higher relative risk of giant cell arteritis vs SGLT2 inhibitors, though overall incidence is low.
No difference in long-term all-cause mortality observed with invasive versus conservative management of high-risk chronic coronary disease.
(HealthDay News) — Participating in cancer clinical trials can cause financial burdens due to socioeconomic and logistical factors, but reimbursing patients for these nonmedical expenses costs a ...
LUGPA 2026 hosted a healthcare “Conversation Across the Aisle” featuring Republican Chris Christie and Democrat David Axelrod ...
Artificial intelligence is changing the healthcare landscape across medicine disciplines. A LUGPA panel discussed how AI is ...
CKD alters the gut microbiome, and changes within the gut may, in turn, contribute to complications associated with CKD.² For ...
Dr Ruchika Talwar was a keynote speaker at the LUGPA 2026 annual meeting in a session titled “The Future-Ready Urologist.” ...
This is the first completed phase trial of neoadjuvant SABR before nephrectomy and IVC thrombectomy for renal cell carcinoma ...
Benjamin H. Lowentritt, MD, FACS, LUGPA secretary and this year’s program chair highlighted key sessions that aim to enhance ...
Renal and Urology News sat down with Dr Lowentritt to discuss the value of conducting clinical trials in house.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results